Literature DB >> 19403677

Fibrils of prostatic acid phosphatase fragments boost infections with XMRV (xenotropic murine leukemia virus-related virus), a human retrovirus associated with prostate cancer.

Seunghee Hong1, Eric A Klein, Jaydip Das Gupta, Kirsten Hanke, Christopher J Weight, Carvell Nguyen, Christina Gaughan, Kyeong-Ae Kim, Norbert Bannert, Frank Kirchhoff, Jan Munch, Robert H Silverman.   

Abstract

The xenotropic murine leukemia virus-related virus (XMRV) has recently been detected in prostate cancer tissues and may play a role in tumorigenesis. It is currently unclear how this virus is transmitted and which factors promote its spread in the prostate. We show that amyloidogenic fragments known as semen-derived enhancer of virus infection (SEVI) originating from prostatic acid phosphatase greatly increase XMRV infections of primary prostatic epithelial and stromal cells. Hybrid simian/human immunodeficiency chimeric virus particles pseudotyped with XMRV envelope protein were used to demonstrate that the enhancing effect of SEVI, or of human semen itself, was at the level of viral attachment and entry. SEVI enhanced XMRV infectivity but did not bypass the requirement for the xenotropic and polytropic retrovirus receptor 1. Furthermore, XMRV RNA was detected in prostatic secretions of some men with prostate cancer. The fact that the precursor of SEVI is produced in abundance by the prostate indicates that XMRV replication occurs in an environment that provides a natural enhancer of viral infection, and this may play a role in the spread of this virus in the human population.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19403677      PMCID: PMC2704761          DOI: 10.1128/JVI.00268-09

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  16 in total

Review 1.  Genetic susceptibility and oxidative stress in prostate cancer: integrated model with implications for prevention.

Authors:  Eric A Klein; Graham Casey; Robert Silverman
Journal:  Urology       Date:  2006-12       Impact factor: 2.649

2.  Isolation of human immunodeficiency virus type 1 from semen and vaginal fluids.

Authors:  Ann A Kiessling
Journal:  Methods Mol Biol       Date:  2005

3.  Molecular cloning of cDNA for human prostatic acid phosphatase.

Authors:  L C Yeh; A J Lee; N E Lee; K W Lam; J C Lee
Journal:  Gene       Date:  1987       Impact factor: 3.688

4.  Species-specific, postentry barriers to primate immunodeficiency virus infection.

Authors:  W Hofmann; D Schubert; J LaBonte; L Munson; S Gibson; J Scammell; P Ferrigno; J Sodroski
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

5.  An infectious retrovirus susceptible to an IFN antiviral pathway from human prostate tumors.

Authors:  Beihua Dong; Sanggu Kim; Seunghee Hong; Jaydip Das Gupta; Krishnamurthy Malathi; Eric A Klein; Don Ganem; Joseph L Derisi; Samson A Chow; Robert H Silverman
Journal:  Proc Natl Acad Sci U S A       Date:  2007-01-18       Impact factor: 11.205

6.  A human cell-surface receptor for xenotropic and polytropic murine leukemia viruses: possible role in G protein-coupled signal transduction.

Authors:  J L Battini; J E Rasko; A D Miller
Journal:  Proc Natl Acad Sci U S A       Date:  1999-02-16       Impact factor: 11.205

7.  Clomiphene citrate administration to normogonadotropic subfertile men: blood hormone changes and activation of acid phosphatase in seminal fluid.

Authors:  L Rönnberg; P Vihko; E Sajanti; R Vihko
Journal:  Int J Androl       Date:  1981-06

8.  The cationic properties of SEVI underlie its ability to enhance human immunodeficiency virus infection.

Authors:  Nadia R Roan; Jan Münch; Nathalie Arhel; Walther Mothes; Jason Neidleman; Akiko Kobayashi; Karen Smith-McCune; Frank Kirchhoff; Warner C Greene
Journal:  J Virol       Date:  2008-10-22       Impact factor: 5.103

9.  Characterization of monoclonal antibodies reactive with murine leukemia viruses: use in analysis of strains of friend MCF and Friend ecotropic murine leukemia virus.

Authors:  B Chesebro; W Britt; L Evans; K Wehrly; J Nishio; M Cloyd
Journal:  Virology       Date:  1983-05       Impact factor: 3.616

10.  Identification of a novel Gammaretrovirus in prostate tumors of patients homozygous for R462Q RNASEL variant.

Authors:  Anatoly Urisman; Ross J Molinaro; Nicole Fischer; Sarah J Plummer; Graham Casey; Eric A Klein; Krishnamurthy Malathi; Cristina Magi-Galluzzi; Raymond R Tubbs; Don Ganem; Robert H Silverman; Joseph L DeRisi
Journal:  PLoS Pathog       Date:  2006-03-31       Impact factor: 6.823

View more
  43 in total

1.  XMRV accelerates cellular proliferation, transformational activity, and invasiveness of prostate cancer cells by downregulating p27(Kip1).

Authors:  Jui Pandhare-Dash; Chinmay K Mantri; Yuanying Gong; Zhenbang Chen; Chandravanu Dash
Journal:  Prostate       Date:  2011-09-19       Impact factor: 4.104

2.  Absence of detectable xenotropic murine leukemia virus-related virus in plasma or peripheral blood mononuclear cells of human immunodeficiency virus type 1-infected blood donors or individuals in Africa.

Authors:  Shixing Tang; Jiangqin Zhao; Ragupathy Viswanath; Phillipe N Nyambi; Andrew D Redd; Armeta Dastyar; Lisa A Spacek; Thomas C Quinn; Xue Wang; Owen Wood; Durga Gaddam; Krishnakumar Devadas; Indira K Hewlett
Journal:  Transfusion       Date:  2010-11-15       Impact factor: 3.157

3.  Characterization of retroviral and lentiviral vectors pseudotyped with xenotropic murine leukemia virus-related virus envelope glycoprotein.

Authors:  Toshie Sakuma; Suk See De Ravin; Jason M Tonne; Tayaramma Thatava; Seiga Ohmine; Yasuhiro Takeuchi; Harry L Malech; Yasuhiro Ikeda
Journal:  Hum Gene Ther       Date:  2010-09-17       Impact factor: 5.695

4.  Inhibition of xenotropic murine leukemia virus-related virus by APOBEC3 proteins and antiviral drugs.

Authors:  Tobias Paprotka; Narasimhan J Venkatachari; Chawaree Chaipan; Ryan Burdick; Krista A Delviks-Frankenberry; Wei-Shau Hu; Vinay K Pathak
Journal:  J Virol       Date:  2010-03-24       Impact factor: 5.103

5.  The amyloidogenic SEVI precursor, PAP248-286, is highly unfolded in solution despite an underlying helical tendency.

Authors:  Jeffrey R Brender; Ravi Prakash Reddy Nanga; Nataliya Popovych; Ronald Soong; Peter M Macdonald; Ayyalusamy Ramamoorthy
Journal:  Biochim Biophys Acta       Date:  2011-01-22

6.  Xenotropic murine leukemia virus-related virus establishes an efficient spreading infection and exhibits enhanced transcriptional activity in prostate carcinoma cells.

Authors:  Jason J Rodriguez; Stephen P Goff
Journal:  J Virol       Date:  2009-12-16       Impact factor: 5.103

7.  Xenotropic murine leukemia virus-related virus is susceptible to AZT.

Authors:  Ryuta Sakuma; Toshie Sakuma; Seiga Ohmine; Robert H Silverman; Yasuhiro Ikeda
Journal:  Virology       Date:  2009-12-02       Impact factor: 3.616

8.  Inhibition of semen-derived enhancer of virus infection (SEVI) fibrillogenesis by zinc and copper.

Authors:  Sarah R Sheftic; Jessica M Snell; Suman Jha; Andrei T Alexandrescu
Journal:  Eur Biophys J       Date:  2012-08-21       Impact factor: 1.733

9.  Susceptibility of the human retrovirus XMRV to antiretroviral inhibitors.

Authors:  Robert A Smith; Geoffrey S Gottlieb; A Dusty Miller
Journal:  Retrovirology       Date:  2010-08-31       Impact factor: 4.602

10.  Lack of evidence for xenotropic murine leukemia virus-related virus(XMRV) in German prostate cancer patients.

Authors:  Oliver Hohn; Hans Krause; Pia Barbarotto; Lars Niederstadt; Nadine Beimforde; Joachim Denner; Kurt Miller; Reinhard Kurth; Norbert Bannert
Journal:  Retrovirology       Date:  2009-10-16       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.